1. What is Ajovy, and how does it work?
Answer: Ajovy (fremanezumab) is a calcitonin gene-related peptide (CGRP) antagonist that blocks a key protein involved in migraine attacks. It’s given as a monthly 225 mg injection and is now FDA-approved for children 6+ weighing ≥45 kg (99 lbs).
2. Who can use Ajovy?
Answer: Approved for:
✔ Adults (chronic/episodic migraine)
✔ Children & teens 6-17 (episodic migraine only)
✔ Patients ≥45 kg (99 lbs)
3. How is Ajovy administered?
Answer:
- Prefilled autoinjector or syringe
- Given by a doctor or self-administered at home
- No starting dose required
4. What are the side effects of Ajovy in kids?
Answer: Most common:
- Injection site reactions (redness, pain)
- Rare but serious risks: hypertension, Raynaud’s phenomenon, allergic reactions
5. How effective is Ajovy for pediatric migraines?
Answer: Clinical trials show reduced migraine frequency in children, similar to adult studies. Exact pediatric efficacy data will be updated post-launch.
Comparison Table: Ajovy vs. Other Pediatric Migraine Treatments
| Treatment | Type | Age Range | Administration | Key Benefit |
|---|---|---|---|---|
| Ajovy | CGRP inhibitor | 6+ (≥45 kg) | Monthly injection | First FDA-approved CGRP for kids |
| Topiramate | Anticonvulsant | 12+ | Daily pill | Generic, but cognitive side effects |
| Amitriptyline | Antidepressant | 10+ | Daily pill | Cheap, but sedation risk |
| Botox | Neurotoxin | 18+ (off-label in teens) | Quarterly injections | Only for chronic migraine |
“Pediatric migraine is a complex condition that can significantly impact a child’s daily life, from school performance to emotional well-being,” Jennifer McVige, M.D., from the DENT Neurologic Institute in Buffalo, New York, said in a statement. “Having an FDA-approved treatment like Ajovy offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.”
Key Takeaways for Parents & Doctors
✅ First CGRP blocker approved for kids – A major milestone in pediatric neurology.
✅ Monthly dosing – Easier than daily pills for adherence.
✅ Home administration – Reduces clinic visits.
⚠ Weight requirement – Only for children ≥99 lbs (45 kg).
Expert Quote
“Pediatric migraine is often dismissed as ‘just a headache,’ but it can devastate a child’s education and social life. Ajovy’s approval means we finally have a targeted, FDA-backed option for prevention.”
— Dr. Jennifer McVige, Pediatric Neurologist, DENT Institute
Conclusion
The FDA’s approval of Ajovy for children 6+ fills a critical gap in migraine care. With at-home use and proven efficacy, it could transform treatment for young patients.
Next Steps:
- Consult a pediatric neurologist if your child has ≥4 migraine days/month.
- Download the Ajovy Prescribing Info here.
